Pharmalink makes board appointments
This article was originally published in Scrip
Executive Summary
The privately held Swedish speciality pharmaceutical company Pharmalink has appointed Anders Wiklund and Dr Jens Christensen to its board of directors. Mr Wiklund has been an advisor to the biotechnology industry since 1997, when he founded Wiklund International. Dr Kristensen is vice-president of clinical development at the Swedish drug development company KaroBio. In addition, Dr Lennart Hansson, director of the life sciences business area at Industrifonden, an independent foundation founded in 1979, joins Pharmalink's board as the Industrifonden representative. Dr Hansson, who has experience in the life science sector having worked at KabiGen, Symbicom, AstraZeneca, Arexis, Biovitrum and Karolinska Development, replaces retiring board member Professor Jörgen Lönngren.
You may also be interested in...
Morgan Lewis expands FDA & healthcare practice
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma appoints new member to board
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
Optimer expands management team
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.